Uncategorized

Lenvatinib Warrants Further Study in mRCC

Lenvatinib added to everolimus extended overall survival (OS) significantly compared with everoli­mus alone in patients with metastatic renal cell carcinoma (mRCC). This phase 2 study also demonstrated improved progression-free survival (PFS) with lenvatinib alone and in combination with everolimus compared with everolimus alone. The OS finding was a secondary end [ Read More ]

Clues to Patient Selection for Lenvatinib in Thyroid Cancer

Lenvatinib was approved by the FDA in February of this year for the treatment of patients with advanced 131I-refractory differentiated thyroid cancer based on results from the SELECT trial. However, it is important to identify which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At ASCO, 2 [ Read More ]

Case: “Difficult-to-Operate” Basal Cell Carcinoma

Surgery may not be appropriate in advanced basal cell carcinoma (BCC), such as those in difficult-to-treat locations or when the deformity would be substantial. At the Third Annual World Cutaneous Malignancies Congress, a panel discussed a complex case of advanced BCC, offering their opinions on the need for imaging, surgery, [ Read More ]

CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Review of the Phase 1 Clinical Trials

Outcomes in adult acute lymphoblastic leukemia (ALL) remain poor, with long-term disease-free survival rates of 30% to 40%.1 Salvage chemotherapy regimens demonstrate limited success in inducing and maintaining a second remission, and consequently overall survival (OS) at 5 years after relapse is as low as 7%.2 Patients who achieve a [ Read More ]

Vaccines for the Treatment of Non–Small Cell Lung Cancer (NSCLC)

Although vaccines are not yet a standard procedure in the therapeutic management of patients with NSCLC, they may play an important role in the future Therapeutic cancer vaccines are classified as either whole-cell vaccines (such as the belagenpumatucel-L vaccine, developed from 4 different NSCLC cell lines) or vaccines that target [ Read More ]

Checkpoint Modulation for Lung Cancer

Numerous clinical studies are under way investigating the blockade of inhibitory “checkpoint pathways” to enhance the antitumor immune response One promising approach to treating lung cancer involves augmenting the existing antitumor immune responses through blockade of inhibitory checkpoint pathways (ie, natural mechanisms that serve to limit the immune response).1 Checkpoint [ Read More ]

Genomic Sequencing for Pancreatic Cancer

Just because whole genome sequencing can be done on a patient’s tumor doesn’t mean that this will translate to a patient’s getting targeted therapy for identified genetic abnormalities, especially if that patient has pancreatic cancer. In the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial, no patient with an identified genetic [ Read More ]

PARP Inhibitor and PI3K Inhibitor Combo in Breast and Ovarian Cancers

Now that a number of targeted therapies are available for the treatment of cancer, one of the big questions is how best to combine them, especially for patients with few other treatment options. Preliminary study shows that combining the PARP inhibitor olaparib with the investigational PI3K inhibitor BKM120 achieves responses [ Read More ]

DNA Blood Testing May Be an Alternative to Tumor Sampling for Identifying EGFR Mutations

Circulating cancer DNA in the blood of cancer patients appears to be able to provide information similar to that obtained from tumor tissue sampling, according to a study presented at the European Lung Cancer Conference. This makes blood testing for DNA an attractive option in cases where tumor tissue is [ Read More ]

The RET Oncogene in Non–Small Cell Lung Cancer: Review of the Current Literature and Directions for the Future

Despite recent advances, lung cancer remains the leading cause of cancer-related death worldwide.1 In the past decade, the treatment of non–small cell lung cancer (NSCLC), which was once a disease with exceedingly few treatment options and historically poor outcomes, has begun to transform. The discovery of targetable cancer-driving mutations has [ Read More ]

Sign me up!